Matrix metalloproteinases as targets for therapy in Kaposi sarcoma.
Acquired immune deficiency syndrome-associated Kaposi sarcoma is a progressive and occasionally fatal condition. The strong angiogenic component of this disease makes it particularly suitable for treatment with the emerging class of drugs that act as antiangiogenic agents. Matrix metalloproteinases have been shown to play prominent roles in the angiogenic process, and small molecule inhibitors of these enzymes are currently being tested as antiangiogenic agents in various malignancies. Given that matrix metalloproteinases contribute to multiple steps of the angiogenic process, inhibitors of these enzymes, either alone or in combination with other agents, may represent a particularly effective therapeutic approach for Kaposi sarcoma.
Fingleton
B
B
Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Matrisian
L M
LM
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D006801:Humans; D020782:Matrix Metalloproteinases / Q000494:pharmacology*; D009389:Neovascularization, Pathologic; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000473:pathology* / Q000821:virology
D020533:Angiogenesis Inhibitors; D020782:Matrix Metalloproteinases